Previous 10 | Next 10 |
2023-07-09 23:52:19 ET Summary The FDA has granted full approval to Biogen and Eisai’s anti-amyloid antibody drug Leqembi, but there is skepticism about its efficacy and safety. The approval led to a drop in Biogen's stock, in part due to the FDA's warning about potential s...
2023-07-09 12:00:00 ET Despite a disappointing start to 2023, the healthcare sector has several promising industries waiting to outperform this year, Goldman Sachs said in a recent report after the bank concluded its annual healthcare conference in Dana Point, California, last month. Th...
2023-07-09 10:00:00 ET Summary The FDA has approved Eisai Co.'s Leqembi label last week, developed with Biogen, for the potential treatment of adult patients with Alzheimer's Disease. The company will lead global development and handle all regulatory submissions for Leqembi, with ...
2023-07-09 06:00:00 ET Biogen (NASDAQ: BIIB) once stood out as one of the most successful biotech companies. It's portfolio of blockbuster multiple sclerosis drugs grew revenue into the billions of dollars. But as the company's top drugs faced losses of exclusivity, Biogen started t...
2023-07-08 14:00:00 ET With the granting of full approval to Biogen ( NASDAQ: BIIB ) and Eisai's ( OTCPK:ESALF ) Leqembi (lecanemab) by the US FDA on July 6, sales are set to take off as Medicare will now cover the Alzheimer's therapy. With an annual list price of $26.5K, Le...
2023-07-07 14:32:50 ET Biogen Inc ( NASDAQ: BIIB ) is trading down this morning even though the Food and Drug Administration awarded full approval to its Alzheimer’s drug – Leqembi. Analyst shares his view on Leqembi The antibody treatment that Biogen makes in ...
2023-07-07 11:24:23 ET Summary Cassava stock crashed in reaction to top-line data from a Phase 2 trial. Both treatment and placebo groups showed little decline on a cognitive test. Market doesn’t realize patient and design characteristics differ from past studies. ...
2023-07-07 10:20:40 ET Summary Esai and Biogen's Alzheimer's Disease therapeutic, Leqembi, received full FDA approval on July 6th. Full approval likely means at least $100s millions/annual revenue since Medicare will reimbursement most of the patient cost for Leqembi. With the...
FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease PR Newswire The first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline in adults with Alzheimer's...
2023-07-06 18:28:00 ET Quanterix ( NASDAQ: QTRX ) said that it has launched a biomarker blood test called LucentAD to help diagnose patients experiencing symptoms consistent with early Alzheimer's disease, or AD. The diagnostics company said the test allows healthcare profession...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...